Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpuraLinus A. Völker, H Felten, Benedikt Kolbrink et al.|Journal of Thrombosis and Haemostasis|2023Cited by 50
Intensive consolidation with G‐CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 yearsWolfgang R. Sperr, Peter Valent, Susanne Herndlhofer et al.|American Journal of Hematology|2017Cited by 11
Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 YearsWolfgang R. Sperr, Peter Valent, Susanne Herndlhofer et al.|Blood|2016Cited by 1
Management of Immune Thrombotic Thrombocytopenic Purpura Without Therapeutic Plasma ExchangeLucas Kühne, Paul T. Brinkkoetter, Paul Knoebl et al.|SSRN Electronic Journal|2023Cited by 1
OC 14.5 Plasma Exchange-free Management of Immune Thrombotic Thrombocytopenic Purpura: The Austrian-German ExperienceLiesbeth C. Kühne, L. Völker, Paul Knoebl et al.|Research and Practice in Thrombosis and Haemostasis|2023Cited by 0